Risk of cardiovascular events in people prescribed glucocorticoids with iatrogenic Cushing's syndrome: Cohort study

BMJ (Online)

Volumn 345, Issue 7871, 2012, Pages

  Fardet, Laurence ^a,b,c   Petersen, Irene ^a   Nazareth, Irwin ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b HÔPITAL SAINT ANTOINE   (France)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; GLUCOCORTICOID;

ADULT; AGE; AGED; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CUSHING SYNDROME; FEMALE; GENERAL PRACTICE; HAZARD RATIO; HEART FAILURE; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; UNITED KINGDOM; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; IATROGENIC DISEASE; MIDDLE AGED; MULTICENTER STUDY; RISK FACTOR;

AGED; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CUSHING SYNDROME; FEMALE; GLUCOCORTICOIDS; GREAT BRITAIN; HUMANS; IATROGENIC DISEASE; INCIDENCE; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84865426589     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e4928     Document Type: Article

References (40)

1. Fardet L, Petersen I, Nazareth I. Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years. Rheumatology (Oxford) 2011;50:1982-90.
2. Van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C. Use of oral corticosteroids in the United Kingdom. Q J Med 2000;93:105-11. (Pubitemid 30098773)
3. Fardet L, Flahault A, Kettaneh A, Tiev KP, Généreau T, Tolédano C, et al. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion. Br J Dermatol 2007;157:142-8. (Pubitemid 46934268)
4. Schou AJ, Heuck C, Wolthers OD. Differential effects of short-term prednisolone treatment on peripheral and abdominal subcutaneous thickness in children assessed by ultrasound. Steroids 2003;68:525-31. (Pubitemid 36945407)
5. Capeau J, Magré J, Caron-Debarle M, Lagathu C, Antoine B, Béréziat V, et al. Human lipodystrophies: genetic and acquired diseases of adipose tissue. Endocr Dev 2010;19:1-20.
6. Fardet L, Cabane J, Kettaneh A, Lebbé C, Flahault A. Corticosteroid-induced lipodystrophy is associated with features of the metabolic syndrome. Rheumatology (Oxford) 2007;46:1102-6. (Pubitemid 47053780)
7. Misra A, Garg A. Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature. Medicine (Baltimore) 2003;82:129-46. (Pubitemid 36331644)
8. Hegele RA. Premature atherosclerosis associated with monogenic insulin resistance. Circulation 2001;103:2225-9. (Pubitemid 32433709)
9. Guaraldi G, Stentarelli C, Zona S, Orlando G, Carli F, Ligabue G, et al. Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects. Atherosclerosis 2010;208:222-7.
10. Thiébaut R, Daucourt V, Mercié P, Ekouévi DK, Malvy D, Morlat P, et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Clin Infect Dis 2000;31:1482-7.
11. Souverein PC, Berard A, Van Staa TP, Cooper C, Egberts AC, Leufkens HG, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 2004;90:859-65. (Pubitemid 39005927)
12. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004;141:764-70.
13. Varas-Lorenzo C, Rodriguez LA, Maguire A, Castellsague J, Perez-Gutthann S. Use of oral corticosteroids and the risk of acute myocardial infarction. Atherosclerosis 2007;192:376-83. (Pubitemid 46745271)
14. Lis Y, Mann RD. The VAMP Research multi-purpose database in the UK. J Clin Epidemiol 1995;48:431-43.
15. Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care 2004;12:171-7. (Pubitemid 39534583)
16. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007;16:393-401. (Pubitemid 46656860)
17. Ruigómez A, Martín-Merino E, Rodríguez LA. Validation of ischemic cerebrovascular diagnoses in the health improvement network (THIN). Pharmacoepidemiol Drug Saf 2010;19:579-85.
18. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010;69:4-14.
19. Lewis JD, Bilker WB, Weinstein RB, Strom BL. The relationship between time since registration and measured incidence rates in the General Practice Research Database. Pharmacoepidemiol Drug Saf 2005;14:443-51. (Pubitemid 40990739)
20. British national formulary. 2011. http://bnf.org/bnf/.
21. Chisholm J. The Read clinical classification. BMJ 1990;300:1092. (Pubitemid 20158094)
22. Davé S, Petersen I. Creating medical and drug code lists to identify cases in primary care databases. Pharmacoepidemiol Drug Saf 2009;18:704-7.
23. Capeau J, Magré J, Lascols O, Caron M, Béréziat V, Vigouroux C, et al. Diseases of adipose tissue: genetic and acquired lipodystrophies. Biochem Soc Trans 2005;33:1073-7. (Pubitemid 41659116)
24. Garg A. Acquired and inherited lipodystrophies. N Engl J Med 2004;350:1220-34. (Pubitemid 38339366)
25. Krikorian A, Khan M. Is metabolic syndrome a mild form of Cushing's syndrome? Rev Endocr Metab Disord 2010;11:141-5.
26. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect "Cushing's disease of the omentum"? Lancet 1997;349:1210-3. (Pubitemid 27190044)
27. Fardet L, Cabane J, Lebbé C, Morel P, Flahault A. Incidence and risk factors for corticosteroid-induced lipodystrophy: a prospective study. J Am Acad Dermatol 2007;57:604-9. (Pubitemid 47384921)
28. Fardet L, Antuna-Puente B, Vatier C, Cervera P, Touati A, Simon T, et al. Adipokine profile in glucocorticoid-treated patients: baseline plasma leptin level predicts occurrence of lipodystrophy. Clin Endocrinol (Oxf) 2012 Jan 24. [Epub ahead of print.]
29. Arena C, Morin AS, Blanchon T, Hanslik T, Cabane J, Dupuy A, Fardet L. Impact of glucocorticoid-induced adverse events on adherence in patients receiving long-term systemic glucocorticoid therapy. Br J Dermatol 2010;163:832-7.
30. Strohmayer EA, Krakoff LR. Glucocorticoids and cardiovascular risk factors. Endocrinol Metab Clin North Am 2011;40:409-17.
31. Horber FF, Zürcher RM, Herren H, Crivelli MA, Robotti G, Frey FJ. Altered body fat distribution in patients with glucocorticoid treatment and in patients on long-term dialysis. Am J Clin Nutr 1986;43:758-69. (Pubitemid 16088972)
32. Lupsa BC, Sachdev V, Lungu AO, Rosing DR, Gorden P. Cardiomyopathy in congenital and acquired generalized lipodystrophy: a clinical assessment. Medicine (Baltimore) 2010;89:245-50.
33. Utz W, Engeli S, Haufe S, Kast P, Hermsdorf M, Wiesner S, et al. Myocardial steatosis, cardiac remodelling and fitness in insulin-sensitive and insulin-resistant obese women. Heart 2011;97:1585-9.
34. Szczepaniak LS, Victor RG, Orci L, Unger RH. Forgotten but not gone: the rediscovery of fatty heart, the most common unrecognized disease in America. Circ Res 2007;101:759-67. (Pubitemid 350287190)
35. McGavock JM, Lingvay I, Zib I, Tillery T, Salas N, Unger R, et al. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation 2007;116:1170-5. (Pubitemid 47360218)
36. Trementino L, Arnaldi G, Appolloni G, Daidone V, Scaroni C, Casonato A, et al. Coagulopathy in Cushing's syndrome. Neuroendocrinology 2010;92(Suppl 1):55-9.
37. Torén K, Lindholm NB. Do patients with severe asthma run an increased risk from ischaemic heart disease? Int J Epidemiol 1996;25:617-20. (Pubitemid 26229564)
38. Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010;137:1091-7.
39. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94. (Pubitemid 24115934)
40. Uddhammar A, Eriksson AL, Nyström L, Stenling R, Rantapää-Dahlqvist S. Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden. J Rheumatol 2002;29:737-42. (Pubitemid 34308459)